Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2008 | Original article

PET/CT with Gluc-Lys-([¹⁸F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions

Authors: Hinrich Wieder, Ambros J. Beer, Thorsten Poethko, Guenther Meisetschlaeger, Hans-Juergen Wester, Ernst Rummeny, Markus Schwaiger, Alexander R. Stahl

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2008

Abstract

Purpose

Somatostatin receptor (sstr) positive tumours vary widely in uptake of radiolabelled somatostatin (sst) analogues. This study determinates variability in lesion uptake of the glycosylated sst analogon N^α-(1-deoxy-d-fructosyl)-N^ɛ-(2-[¹⁸F]fluoropropionyl)-Lys⁰-Tyr³-octreotate (Gluc-Lys([¹⁸F]FP)-TOCA) and correlates it with lesion size and arterial perfusion as measured on computed tomography (CT).

Methods

Ten patients with metastasized neuroendocrine carcinomas were investigated with positron emission tomography PET/CT (Biograph 16, Siemens, Germany). Lesion standardized uptake values (SUVs) were determined at ∼50 min post tracer injection according to a 60% isocontour volume of interest around each lesion. Lesion size and enhancement in the arterial phase (hounsfield units, HUs) were derived from CT.

Results

114 lesions in the upper abdomen had a correlate on both, PET and CT. Variability in lesion SUVs was high (SUV_mean 22 ± 13). Intraindividually, there was a sigmoid positive correlation between lesion SUV and lesion diameter indicating partial volume effects. Residual variability in lesions ≥3 cm (≥2.5 cm) ranged down to about half (third) of the maximum lesion uptake and remained unexplained by partial volume effects. No correlation with measured HU in the arterial phase was found, neither intraindividually nor interindividually.

Conclusion

Partial volume effects were a major source of intraindividual variability in tumour tracer uptake. Lesions below 2.5 to 3 cm should thus be used with caution when performing dose calculations. In larger lesions residual variability in uptake must be considered; it may be due to variable sstr2 expression on the tumours’ cell surfaces.

Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, et al. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med 2006;47:566–73.PubMed

Schottelius M, Poethko T, Herz M, Reubi JC, Kessler H, Schwaiger M, et al. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res 2004;10:3593–606.PubMedCrossRef

Wester HJ, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau FC, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel (18)F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003;30:117–22.PubMedCrossRef

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.PubMedCrossRef

Stahl A, Meisetschlager G, Schottelius M, Bruus-Jensen K, Wolf I, Scheidhauer K, et al. [(123)I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [(111)In]octreotide. Eur J Nucl Med Mol Imaging 2006;33:45–52.PubMedCrossRef

Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging 2002;29:28–38.PubMedCrossRef

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982–93.PubMedCrossRef

Koenig JA, Kaur R, Dodgeon I, Edwardson JM, Humphrey PP. Fates of endocytosed somatostatin sst2 receptors and associated agonists. Biochem J 1998;336 (Pt 2):291–98.PubMed

Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207–16.PubMedCrossRef

10.

Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 1999;26:877–86.PubMedCrossRef

11.

Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004;1014:234–45.PubMedCrossRef

12.

Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12:941–45.PubMedCrossRef

13.

Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610–6.PubMed

14.

Cremonesi M, Ferrari M, Chinol M, Bartolomei M, Stabin MG, Sacco E, et al. Dosimetry in radionuclide therapies with 90Y-conjugates: the IEO experience. Q J Nucl Med 2000;44:325–32.PubMed

15.

Brix G, Bellemann ME, Hauser H, Doll J. [Recovery coefficients for the quantification of the arterial input functions from dynamic PET measurements: experimental and theoretical determination]. Nuklearmedizin 2002;41:184–90.PubMed

Title: PET/CT with Gluc-Lys-([18F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions
Authors: Hinrich Wieder
Ambros J. Beer
Thorsten Poethko
Guenther Meisetschlaeger
Hans-Juergen Wester
Ernst Rummeny
Markus Schwaiger
Alexander R. Stahl
Publication date: 01-02-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0576-1

At a glance: The STEP trials

Springer Medicine

PET/CT with Gluc-Lys-([¹⁸F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2008

Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT: J-ACCESS study

123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma

Determinants of the response of left ventricular ejection fraction to vasodilator stress in electrocardiographically gated 82rubidium myocardial perfusion PET

Wavelet denoising for voxel-based compartmental analysis of peripheral benzodiazepine receptors with 18F-FEDAA1106

Comparison of SSS and SRS calculated from normal databases provided by QPS and 4D-MSPECT manufacturers and from identical institutional normals

Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF